Tsinghua Yuanxing Pharmaceutical

Tsinghua Yuanxing Pharmaceutical is a China-based biopharmaceutical company that emerged from the high-tech industrial initiatives of Tsinghua University. The company is primarily recognized for its pioneering work in gene therapy and oncology, having played a significant role in the industrialization of Gendicine, the world's first commercially approved gene therapy product for head and neck cancer. Beyond gene therapy, the company maintains a diverse portfolio of traditional pharmaceuticals, including anti-infectives and cardiovascular medications. It operates integrated research, development, and manufacturing facilities in Shenzhen, focusing on bridging academic innovation with commercial pharmaceutical production.